Thus, our results show that ADH-6 effectively shrinks tumors bearing aggregation-prone mutant p53 in vivo, without displaying the non-specific toxicity that is common to conventional cancer therapeutics, thereby greatly prolonging survival. Here, TP53 is linked to cancer.